These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 15815877

  • 1. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.
    White MM, Krishnan R, Kueter TJ, Jacoski MV, Jennings LK.
    J Thromb Thrombolysis; 2004 Dec; 18(3):163-9. PubMed ID: 15815877
    [Abstract] [Full Text] [Related]

  • 2. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.
    Simon DI, Liu CB, Ganz P, Kirshenbaum JM, Piana RN, Rogers C, Selwyn AP, Popma JJ.
    Catheter Cardiovasc Interv; 2001 Apr; 52(4):425-32. PubMed ID: 11285593
    [Abstract] [Full Text] [Related]

  • 3. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
    Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC.
    Am Heart J; 2002 Apr; 143(4):602-11. PubMed ID: 11923796
    [Abstract] [Full Text] [Related]

  • 4. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
    Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, Mascelli MA, Marciniak SJ, Just A, Lösche W, Breddin HK.
    Thromb Res; 2001 Apr 01; 102(1):39-48. PubMed ID: 11323013
    [Abstract] [Full Text] [Related]

  • 5. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Voss R.
    J Thromb Thrombolysis; 2001 Oct 01; 12(2):129-39. PubMed ID: 11729364
    [Abstract] [Full Text] [Related]

  • 6. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 01; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 7. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
    Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ.
    Circulation; 2001 May 29; 103(21):2572-8. PubMed ID: 11382726
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP, Schuster P.
    Z Kardiol; 2003 Mar 29; 92(3):213-8. PubMed ID: 12658467
    [Abstract] [Full Text] [Related]

  • 9. Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study.
    Saucedo JF, Lui HK, Garza L, Guerra GJ, Jacoski MV, Jennings LK.
    J Thromb Thrombolysis; 2004 Oct 29; 18(2):67-74. PubMed ID: 15789173
    [Abstract] [Full Text] [Related]

  • 10. Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors.
    Lakkis NM, George S, Thomas E, Ali M, Guyer K, Carville D.
    Catheter Cardiovasc Interv; 2001 Jul 29; 53(3):346-51. PubMed ID: 11458412
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of abciximab induced platelet blockade using a rapid point of care assay.
    Kereiakes DJ, Mueller M, Howard W, Lacock P, Anderson LC, Broderick TM, Roth EM, Whang DD, Abbottsmith CW.
    J Thromb Thrombolysis; 1999 Jun 29; 7(3):265-76. PubMed ID: 10375388
    [Abstract] [Full Text] [Related]

  • 12. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
    Lakkis N, Lakiss N, Bobek J, Farmer J.
    Catheter Cardiovasc Interv; 2002 Aug 29; 56(4):474-7. PubMed ID: 12124955
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE, Gupta R, Rajendran S, Luu J, French JK, Juergens CP.
    Cardiovasc Ther; 2016 Oct 29; 34(5):330-6. PubMed ID: 27327862
    [Abstract] [Full Text] [Related]

  • 14. Plateletworks: a novel point of care platelet function screen.
    Campbell J, Ridgway H, Carville D.
    Mol Diagn Ther; 2008 Oct 29; 12(4):253-8. PubMed ID: 18652521
    [Abstract] [Full Text] [Related]

  • 15. Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.
    Puri A, Bansal A, Narain VS, Sethi R, Dwivedi SK, Puri VK, Saran RK.
    Indian Heart J; 2013 Oct 29; 65(2):152-7. PubMed ID: 23647894
    [Abstract] [Full Text] [Related]

  • 16. Rapid platelet-function assay: an automated and quantitative cartridge-based method.
    Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS.
    Circulation; 1999 Feb 09; 99(5):620-5. PubMed ID: 9950658
    [Abstract] [Full Text] [Related]

  • 17. A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel.
    van Werkum JW, Kleibeuker M, Postma S, Bouman HJ, Elsenberg EH, ten Berg JM, Hackeng CM.
    Int J Cardiol; 2010 Apr 01; 140(1):123-6. PubMed ID: 19091430
    [Abstract] [Full Text] [Related]

  • 18. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
    Pontiggia L, Steiner B, Ulrichts H, Deckmyn H, Forestier M, Beer JH.
    Thromb Haemost; 2006 Dec 01; 96(6):774-80. PubMed ID: 17139372
    [Abstract] [Full Text] [Related]

  • 19. Point-of-care assessment of antiplatelet agents in the perioperative period: a review.
    Gibbs NM.
    Anaesth Intensive Care; 2009 May 01; 37(3):354-69. PubMed ID: 19499855
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C, Badar J, Covic L, Waxman S, Weintraub A, Jacques S, Kuliopulos A.
    Thromb Res; 2005 May 01; 116(1):55-66. PubMed ID: 15850609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.